Repligen Corporation, a key player in bioprocessing solutions, announced the election of Dr. Martin D. Madaus as the new Chair of the Board.
The current Executive Chair, Tony Hunt, will retire from his position, effective March 13, 2026, paving the way for Dr. Madaus to assume leadership.
With a wealth of experience in the bioprocessing industry, Dr. Madaus is well-positioned to steer Repligen towards further success and innovation.
Leadership Change
Dr. Martin D. Madaus takes over from Tony Hunt as Chair of the Board, bringing a deep understanding of bioprocessing technologies and industry dynamics, suggesting a strategic alignment with Repligen's core operations.
Tony Hunt's Retirement
Tony Hunt, stepping down as Executive Chair, will transition to an advisory role at Repligen until March 2027, ensuring continuity and leveraging his insights for a smooth succession process.
Company Appreciation
Olivier Loeillot, CEO of Repligen, expressed gratitude for Tony Hunt's invaluable contributions, underscoring the robust groundwork laid for future growth and evolution under Dr. Madaus's stewardship.
- Dr. Martin D. Madaus's distinguished background in bioprocessing endorses him as a fitting Chair of the Board, poised to leverage his expertise for strategic decision-making and fostering innovation within Repligen's operations.
- The leadership transition from Tony Hunt to Dr. Madaus represents a deliberate shift towards sustained growth and advancement, signaling Repligen's intent to capitalize on emerging opportunities and further solidify its market presence.
Dr. Madaus's appointment as Chair heralds a new era of growth and innovation for Repligen Corporation, capitalizing on its strong foundation and market positioning. The succession from Tony Hunt underscores the company's unwavering pursuit of excellence and domain-specific leadership.